(USD) | Sep 2023 | Q/Q |
---|---|---|
Revenue | 511MM | +9% |
Gross Profit | - | - |
Cost Of Revenue | - | - |
Operating Income | -17.9MM | -17% |
Operating Expenses | - | - |
Net Income | -25.3MM | -26% |
R&D | - | - |
G&A | 96.6MM | +7% |
Amortization | 23.8MM | -1% |
Interest Expense | 14.6MM | +1% |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
The average of price targets set by Wall Street analysts indicates a potential upside of 34.5% in Evolent Health (EVH). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
The consensus price target hints at a 35.7% upside potential for Evolent Health (EVH). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Shareholders of Evolent Health, Inc. ( NYSE:EVH ) will be pleased this week, given that the stock price is up 10% to...
Evolent Health ( NYSE:EVH ) Full Year 2023 Results Key Financial Results Revenue: US$1.96b (up 45% from FY 2022). Net...
Evolent Health, Inc. (NYSE:EVH) Q4 2023 Earnings Call Transcript February 22, 2024 Evolent Health, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Welcome to the Evolent Earnings Conference Call for the Quarter and Year-Ended December 31, 2023. As a […]
Q4 2023 Evolent Health Inc Earnings Call
EVH earnings call for the period ending December 31, 2023.
Full Year Revenue Surges by 45% with Adjusted EBITDA Climbing 84% Year-Over-Year
Evolent Health, Inc. (NYSE: EVH), a company that specializes in better health outcomes for people with complex conditions through proven solutions that make health care simpler and more affordable, today announced financial results for the three months and year ended December 31, 2023.
Evolent Health, Inc. (NYSE: EVH), a company that specializes in better health outcomes for people with complex conditions through proven solutions that make health care simpler and more affordable, today appointed Russell Glass to its Board of Directors. Glass has almost 25 years of experience as a successful technology and health care executive who currently serves as Chief Executive Officer of Headspace, a pioneering company focused on digitally enabled mental health support for employers, hea